Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy

被引：0
|
作者：
Lee, A. [1 ]
Girling, B. [1 ]
Patel, G. [1 ]
Sawhney, P. [1 ]
Luong, M. [1 ]
Ohana, D. [1 ]
Forster, M. [1 ]
Lee, S. [1 ]
机构：
[1] Univ Coll London Hosp, Canc Div, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
immunotherapy; NSCLC; Toxicities;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.06
引用
收藏
页码：S925 / S926
页数：2
相关论文
共 50 条
  • [41] Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
    Furubayashi, Nobuki
    Minato, Akinori
    Negishi, Takahito
    Sakamoto, Naotaka
    Song, Yoohyun
    Hori, Yoshifumi
    Tomoda, Toshihisa
    Harada, Mirii
    Tamura, Shingo
    Miura, Akihiro
    Komori, Hiroki
    Kuroiwa, Kentaro
    Seki, Narihito
    Fujimoto, Naohiro
    Nakamura, Motonobu
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1641 - 1651
  • [42] Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy
    Khorasanchi, Adam
    Zhao, Songzhu
    Wei, Lai
    Li, Mingjia
    Ho, Kevin
    Abu-Sbeih, Hamzah
    Goodyear, Evelyn
    Secor, Austin
    Shields, Peter G.
    He, Kai
    Kaufman, Jacob
    Memmott, Regan
    Alahmadi, Asrar
    Carbone, David
    Otterson, Gregory A.
    Meara, Alexa
    Presley, Carolyn J.
    Owen, Dwight H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E16 - E16
  • [43] Analysis of Immune-Related Adverse Events of Pembrolizumab Using FAERS Database
    Tan, Feilong
    Zhou, Li
    Huang, Guijiang
    Li, Yanhua
    Yin, Wenjie
    Xia, Hongying
    ONCOLOGY, 2025,
  • [44] Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response
    Rogado, J.
    Pacheco Barcia, V.
    Vera, B.
    Toquero, P.
    Mondejar, R.
    Ballesteros Garcia, A. I.
    Donnay, O.
    Romero Laorden, N.
    Colomer Bosch, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S112 - S112
  • [45] Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs
    Giommoni, Elisa
    Pillozzi, Serena
    Ottanelli, Carlotta
    Cosso, Federica
    Caliman, Enrico
    Mazzoni, Francesca
    Fancelli, Sara
    Lavacchi, Daniele
    Brugia, Marco
    Pellegrini, Elisa
    Vannini, Agnese
    Napolitano, Brunella
    Sanza, Roberta Fuccio
    Shabani, Sonia
    Zepponi, Francesca
    Pasqui, Adriano
    Zenoni, Andrea
    Antonuzzo, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor
    Yu, Jia
    Xiong, Fen
    Xu, Yingruo
    Xu, Hanyan
    Zhang, Xi
    Gao, Hongchang
    Li, Yuping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [47] Association of immune-related adverse events, inflammatory biomarkers, and clinical outcomes in patients treated with ICIs for advanced renal cell carcinoma
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Goswamy, Rohit Vivek
    Choi, Yujin
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab plus AVD for Classic Hodgkin Lymphoma
    Kuczmarski, Thomas M.
    Ujjani, Chaitra S.
    Poh, Christina
    Warren, Edus H.
    Smith, Stephen D.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Tseng, Yolanda
    Du, Hongyan
    Vandermeer, Jacquelin
    Kelly, Alyssa
    Rasmussen, Heather
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    Lynch, Ryan C.
    BLOOD, 2024, 144 : 1667 - 1668
  • [49] Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
    Yoshiyasu Kono
    Yasuhiro Choda
    Masahiro Nakagawa
    Koji Miyahara
    Michihiro Ishida
    Tetsushi Kubota
    Keiji Seo
    Tetsu Hirata
    Yuka Obayashi
    Tatsuhiro Gotoda
    Yuki Moritou
    Yoshiko Okikawa
    Yasuo Iwamoto
    Hiroyuki Okada
    Targeted Oncology, 2021, 16 : 237 - 248
  • [50] Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
    Kono, Yoshiyasu
    Choda, Yasuhiro
    Nakagawa, Masahiro
    Miyahara, Koji
    Ishida, Michihiro
    Kubota, Tetsushi
    Seo, Keiji
    Hirata, Tetsu
    Obayashi, Yuka
    Gotoda, Tatsuhiro
    Moritou, Yuki
    Okikawa, Yoshiko
    Iwamoto, Yasuo
    Okada, Hiroyuki
    TARGETED ONCOLOGY, 2021, 16 (02) : 237 - 248
12345